pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Myqorzo · news · pharmadog
← back to Myqorzo
News mentioning Myqorzo
14
stories
6d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
14d
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
14d
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
21d
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jul 15, 26
Braveheart, Attovia join next wave of biotech IPOs
biopharma dive
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 16, 26
Edgewise heart drug passes key trial test
biopharma dive
May 7, 26
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
stat
May 6, 26
STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
stat
May 5, 26
STAT+: Are analysts too quick to gloss over Lilly’s liver case?
stat
May 5, 26
Cytokinetics heart drug scores in closely watched trial
biopharma dive
May 5, 26
Cytokinetics succeeds where Bristol Myers failed in heart muscle disease
endpoints
May 5, 26
STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
stat
